An Interleukin-1 Signature in Breast Cancer Treated with Interleukin-1 Receptor Blockade: Implications for Treating Cytokine Release Syndrome of Checkpoint Inhibitors
- 14 September 2018
- journal article
- editorial
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 78 (18) , 5200-5202
Abstract
In this issue of Cancer Research, Wu and colleagues show that IL1b orchestrates tumor-promoting inflammation in breast cancer and can be targeted in patients using an IL1 receptor antagonist. Cancer Res; 78(18); 5200–2. ©2018 AACR. See related article by Wu et al., p. 5243Keywords
Funding Information
- NIH (AI-15614)
- NIH (GM046883, GM113943, HD076125, HL131182, HD090637)
This publication has 11 references indexed in Scilit:
- IL1 Receptor Antagonist Controls Transcriptional Signature of Inflammation in Patients with Metastatic Breast CancerCancer Research, 2018
- Fluorouracil and bevacizumab plus anakinra for patients with metastatic colorectal cancer refractory to standard therapies (IRAFU): a single-arm phase 2 studyOncoImmunology, 2018
- Abstract 5243: Prognostic value of nuclear and non-nuclear estrogen receptor expression by immunohistochemistry with phosphor-integrated dots in hormone receptor-positive early breast cancerCancer Research, 2018
- A tumor–myeloid cell axis, mediated via the cytokines IL-1α and TSLP, promotes the progression of breast cancerNature Immunology, 2018
- IL‐1 and IL‐1 regulatory pathways in cancer progression and therapyImmunological Reviews, 2017
- Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trialThe Lancet, 2017
- MABp1 as a novel antibody treatment for advanced colorectal cancer: a randomised, double-blind, placebo-controlled, phase 3 studyThe Lancet Oncology, 2017
- Reduction in C‐reactive protein indicates successful targeting of the IL‐1/IL‐6 axis resulting in improved survival in early stage multiple myelomaAmerican Journal of Hematology, 2016
- Treating inflammation by blocking interleukin-1 in a broad spectrum of diseasesNature Reviews Drug Discovery, 2012
- Why not treat human cancer with interleukin-1 blockade?Cancer and Metastasis Reviews, 2010